ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 64 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,288 | +13.3% | 2,126 | +104.0% | 0.00% | – |
| Q2 2023 | $9,964 | +38.4% | 1,042 | +62.3% | 0.00% | – |
| Q1 2023 | $7,199 | -10.0% | 642 | +18.5% | 0.00% | – |
| Q4 2022 | $8,000 | -11.1% | 542 | +18.6% | 0.00% | – |
| Q3 2022 | $9,000 | -18.2% | 457 | 0.0% | 0.00% | – |
| Q2 2022 | $11,000 | +37.5% | 457 | +14.2% | 0.00% | – |
| Q1 2022 | $8,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q4 2021 | $8,000 | -55.6% | 400 | -45.2% | 0.00% | – |
| Q3 2021 | $18,000 | -76.0% | 730 | -73.6% | 0.00% | – |
| Q2 2021 | $75,000 | +257.1% | 2,764 | +291.5% | 0.00% | – |
| Q1 2021 | $21,000 | -93.8% | 706 | -94.1% | 0.00% | -100.0% |
| Q4 2020 | $336,000 | +2700.0% | 11,961 | +2890.2% | 0.00% | – |
| Q3 2020 | $12,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q2 2020 | $12,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q1 2020 | $12,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $296,569,000 | 22.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $111,937,000 | 7.03% |
| Pivotal bioVenture Partners Investment Advisor LLC | 671,716 | $18,895,000 | 6.23% |
| Omega Fund Management, LLC | 640,199 | $18,009,000 | 2.70% |
| Orbimed Advisors | 6,073,850 | $170,857,000 | 1.50% |
| Vivo Capital, LLC | 867,170 | $24,393,000 | 1.09% |
| Octagon Capital Advisors LP | 100,000 | $2,813,000 | 0.98% |
| Altium Capital Management LP | 62,962 | $1,771,000 | 0.66% |
| RA Capital Management | 1,165,184 | $32,777,000 | 0.46% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 8,505 | $239,000 | 0.14% |